---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-397219"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2026-09-22T11:06:19+00:00"
generated_at: "2026-09-22T11:10:34.919874+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Viking VK2735: 33-week weight loss 22% via weekly dosing; QOW/QM maintenance holds up to 97%/90%

## Summary
- VK2735 maintenance study (N≈180, BMI≥30): weekly 17.5 mg led to 21.7% mean weight loss from baseline at 33 weeks; placebo gain 0.3%, p<0.0001; no plateau.
- Induction (21 wks weekly): 16-19% weight loss across 15-22.5 mg vs ~0% placebo, p<0.0001; 98% achieved ≥5%, 32% ≥20% loss.
- After transitioning to every-other-week dosing for 12 weeks, maintained up to 97% of Week 21 weight loss vs 61% placebo, p<0.0001.
- Monthly dosing for 12 weeks maintained up to 90% of Week 21 weight loss vs 61% placebo (p=0.0002); separation from placebo by week 4.
- GI AE rates similar to placebo during maintenance; 1% discontinued due to AE in induction; oral maintenance part 2 planned.

## SEC filing metadata
- accession: 0001193125-26-397219
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2026-09-22T11:06:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/0001193125-26-397219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/vktx-20260922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-397219
- JSON: https://secwatch.observer/filing/0001193125-26-397219.json
- Plain text: https://secwatch.observer/filing/0001193125-26-397219.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.